BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype

• DOI: 10.1016/j.ebiom.2023.104738
• Publication Date: 2023-08-05T17:06:37Z
• Authors: Heidi Fettke; Chao Dai; Edmond M. Kwan; Tiantian Zheng; Pan Du; Nicole Ng; Patricia Bukczynska; Maria Docanto; Louise Kostos; Siavash Foroughi; Stephen Brown; Lisa-Jane K. Graham; Kate Mahon; Lisa G. Horvath; Shidong Jia; Manish Kohli; Arun A. Azad
• Keywords: CHEK2

Genomic alterations in DNA damage response (DDR) genes are common metastatic castration-resistant prostate cancer (mCRPC). Understanding how these genomic events impact prognosis and/or treatment is vital for optimising clinical outcomes.